Recent News
Read ArticleDr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.
RT @ericdeinMD
#RNL26 Haque
Effect of GLP1 on Pts with RA
Retrospective study
Significant reduction is RA disease activity (P=0.03), VAS pain (p<0.001), weight, cholesterol and A1c
But 1/3 stopped due to side effects (mostly GI) https://t.co/SNHTcRFmAX
Dr. John Cush @RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Haque
TOGETHER-PsA -P3B study of IXE v IXE + Tirzepatide
BMI >27 + 1 wt related co-morbidity
-Endpts - ACR and >10% weight reduction
-ACR50 improved 33.5% compared to 20% IXE alone (p<0.05) https://t.co/KCpqbg3fHs https://t.co/zktIkdumDk
Links:
Dr. John Cush @RheumNow ( View Tweet)
RT @richardPAconway
We have improved RA mortality in many areas but respiratory (mainly ILD) and infectious issues remain stubbornly elevated. #RNL26 https://t.co/ViucOIOOzY https://t.co/3kIqPMeKKX
Links:
Dr. John Cush @RheumNow ( View Tweet)
RT @richardPAConway
AUC of various published screening strategies for RA-ILD. We often say 0.80 is an acceptable cut off but ideally would like a bit better #RNL26 https://t.co/L19uJ7ETwc
Dr. John Cush @RheumNow ( View Tweet)
RT @RichardPAConway
Odds ratios for ILD in early RA from SAIL-RA study. Again disease activity stands out. #RNL26 https://t.co/9cXjOFl3Th
Dr. John Cush @RheumNow ( View Tweet)
RT @Gibson_RheumPAC
Drug-induced SCLE remains an important mimic in biologic-treated patients. Compared with idiopathic SCLE, drug-induced disease is often more widespread and may resolve with antibody normalization after withdrawal.#RNL26 https://t.co/ICOzg3Tz4L
Dr. John Cush @RheumNow ( View Tweet)
RT @Gibson_RheumPAC
Important rheumatology signal: dupilumab-associated inflammatory arthritis. Usually seronegative, imaging-supported, and sometimes persistent despite normal labs. Co-management and careful work-up are essential.#RNL26 https://t.co/r73cSZC59s
Dr. John Cush @RheumNow ( View Tweet)
RT @@Gibson_RheumPAC
Eczematous eruptions with IL-17 inhibition are increasingly recognized. Registry data suggest higher adjusted incidence with IL-17 inhibitors compared with other biologic classes, especially in older patients and those with atopic history. #RNL26 https://t.co/nvwl5mNg4k
Dr. John Cush @RheumNow ( View Tweet)
Incretins/GLP-1s are being investigated widely. @RWCSmtg #RWCS26 https://t.co/57JzRJfK8l
Dr. John Cush @RheumNow ( View Tweet)
Most inhibition of inflammation is via the brain. More GLP1 and GIP1 receptors are in the brain, more than the gut. @RWCSmtg #RWCS26 https://t.co/CNzUqteBLg
Dr. John Cush @RheumNow ( View Tweet)
The hx and timeline of GLP1a development. @RWCSmtg #RWCS26 https://t.co/7tPgcRy4Ze
Dr. John Cush @RheumNow ( View Tweet)
Dr. Willa Tsueh taking on hx of GLP-1 agonists. The first ones, Victoza and Tulicity go back to 2010. @RWCSmtg #RWCS26 https://t.co/cKiDCM5xw6
Dr. John Cush @RheumNow ( View Tweet)
#RNL26
Haque @HopkinsRheum
1/2 of Americans will be obese by 2030
"Obesity is common & obesity is expensive"
Adipose tissue - active endocrine organ -> cytokines, chemokines, adipokines
Leads to inflamm axis - risk factor similar to 🚬, higher activity, worse response https://t.co/yQLTpE7reY
Dr. John Cush @RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Dx Modification of OA
@Tuhina_Neogi
Challenge in drug develop:
Models in young animal, not like human OA
Trial enrollment in pts w late, establ OA- not early interv tx
Many paths to OA - target mechanism to correct pt
Slow progress of dx, $$
Endpt? Sx or
Dr. John Cush @RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Placebo in Rheumatology - STEP talk
Kerschbaumer
What plays role in PBO?
Treatment adherence effect w better background therapy - may appear to be PBO
Impact in globalization of recruitment patterns, affects background PBO
Education of pts bridges gap
Dr. John Cush @RheumNow ( View Tweet)
RT @richardPAconway
Who to screen for RA-ILD is a tricky one. It is not feasible to screen everyone. This is from ACR/Chest 2023 ILD guidelines and is based on identified risk factors. #RNL26 https://t.co/NtAWYCVclJ
Dr. John Cush @RheumNow ( View Tweet)
RT @richardPAconway Disease activity is a strong risk factor for RA-ILD. Particularly for moderate/high disease activity but there appears to be a linear relationship (at least above a certain threshold) #RNL26 https://t.co/ot8ttdmu5G
Dr. John Cush @RheumNow ( View Tweet)
Vasculitis
Sunday’s vasculitis session at RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field.
https://t.co/ueg3yJDMu4 https://t.co/8uiI9A5G8x
Links:
Dr. John Cush @RheumNow ( View Tweet)
RT @richardPAconway
Lifetime risk of ILD by RA/sex/MUC5B status. We can see the synergistic effect. Also note RA>MUC5B in general. #RNL26 https://t.co/L5MOVVGIt3
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Maui Potpourri (2.13.2026)-
ANA Pollution (2.06.2026)
DERM on RheumNow PODCAST (January 2026)-
RheumNow Live Preview (1.30.2026)
Therapeutic Updates
The Impact of Obesity on Psoriatic Arthritis
Sponsored by Lilly Medical Affairs
Image alt text: A person indoors raises one arm in a flexed pose while holding the elbow with the opposite hand.
Is obesity common in your patients with PsA? Learn more about the intersection of disease pathogenesis between PsA and obesity and how weight intervention can affect PsA outcomes.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
